Europe Anti-Obesity Drugs Market Report and Forecast 2024-2032

Europe Anti-Obesity Drugs Market Outlook

The anti-obesity drugs market size was valued at USD 2.5 billion in 2023, with Europe holding a significant market share. It is driven by the rising prevalence of obesity. The global market is expected to grow at a CAGR of 10.70% during the forecast period of 2024-2032, with the values likely to attain USD 6.3 billion by 2032.

Key Takeaways

• In Europe, the United Kingdom has one of the highest obesity rates, with 27.8% of the population falling under the obese category. The rising prevalence of obesity is expected to drive market demand.

• One of the major Europe anti-obesity drugs market trends is the increased investment in obesity drug production to reduce shortages and improve accessibility for weight loss medications. In November 2023, Novo Nordisk A/S invested USD 2.3 billion in a French facility to fuel the production of its anti-obesity drugs, including Wegovy and Ozempic.

• Expansion in production facilities is poised to address manufacturing needs and stimulate innovation in the anti-obesity drugs in the region. In November 2023, Eli Lilly and Company invested USD 2.5 billion to build a manufacturing plant in Germany to boost the production capacity of its diabetes and obesity drugs including Mounjaro and Trulicity.

Europe Anti-Obesity Drugs Market Analysis

The market is witnessing steady growth driven by the increasing prevalence of obesity in the region. Various factors such as unhealthy eating habits, sedentary lifestyles, and certain genetic predispositions, among others, are resulting in the sharp growth of the bariatric population. In Europe, the United Kingdom has one of the highest obesity rates, with 27.8% of the population falling under the obese category. With the rising obesity prevalence, the Europe anti-obesity drugs market demand is likely to witness a surge owing to the efficacy of these medications in managing weight and reducing associated health risks.

One of the major market trends is the increased investment in anti-obesity drug production by the leading market players to meet the growing demand for weight management medications. In November 2023, the global healthcare company Novo Nordisk A/S invested USD 2.3 billion in a French facility to fuel the production of its anti-obesity drugs. The funding will amplify the manufacturing capacity for Novo’s popular weight loss drugs, Wegovy and Ozempic, along with other obesity treatments under development. Such substantial investments are expected to reduce shortages and improve accessibility for weight loss medications, thereby propelling the Europe anti-obesity drugs market growth in the forecast period.

In November 2023, a similar investment initiative was taken by Eli Lilly and Company, intended to address the soaring demand for anti-obesity drugs in Europe. The company revealed its plan to invest USD 2.5 billion to build a manufacturing plant in Germany to boost the production capacity of its diabetes and obesity drugs such as Mounjaro and Trulicity. The expansion of such production facilities in the region is poised to accommodate manufacturing needs and stimulate innovation in the obesity treatment segment, thereby fuelling market share.

Europe Anti-Obesity Drugs Market Segmentation

The report offers a detailed analysis of the market based on the following segments:

Europe Anti-Obesity Drugs Market: Competitor Landscape

The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• VIVUS Inc

• Pfizer, Inc.

• Novo Nordisk

• Bayer AG

• F. Hoffmann-La Roche

• Glaxosmithkline

• Arena Pharmaceuticals

• Eisai Co. Ltd

• Takeda Pharmaceutical Company

• Nalpropion Pharmaceuticals Inc

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report